Form 4: Teva Pharmaceutical Director Janet Vergis Reports Routine Stock Activity, Including RSU Vesting and New Grant

Teva Pharmaceutical Industries Ltd. Director Janet S. Vergis reported the vesting of 9,632 restricted share units into ordinary shares and the grant of 14,492 new restricted share units.

Summary

• On June 6, 2025, Teva Pharmaceutical Industries Ltd. Director Janet S. Vergis acquired 9,632 Ordinary Shares through the settlement of previously granted Restricted Share Units (RSUs).
• These 9,632 RSUs were originally granted on June 6, 2024, and vested on June 6, 2025.
• Following this transaction, Janet S. Vergis directly beneficially owns 73,697 Ordinary Shares.
• Additionally, on June 5, 2025, Janet S. Vergis was granted 14,492 new Restricted Share Units.
• These newly granted RSUs are scheduled to vest on June 5, 2026.
• Each restricted share unit represents a contingent right to receive one ordinary share or its cash equivalent at the discretion of the Human Resources and Compensation Committee.

Sentiment

Score: 6

Explanation: The document reports routine compensation events (RSU vesting and new grant) for a director, which is generally a neutral to slightly positive signal as it indicates ongoing alignment of interests and retention of key personnel.

Positives

• The vesting of 9,632 Restricted Share Units demonstrates a successful conversion of performance-based compensation into equity for the director.
• The grant of 14,492 new Restricted Share Units indicates continued long-term incentive alignment between the director and shareholder interests, and a commitment to retaining key management.

Future Outlook

The newly granted 14,492 Restricted Share Units are set to vest on June 5, 2026, indicating a future equity compensation event for the director.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is a common practice across the pharmaceutical industry to align management incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The report indicates a director's continued equity ownership and participation in the company's long-term incentive plan, which can be viewed positively as it aligns their interests with shareholder value creation.
• Employees: The compensation structure for directors, including RSU grants, reflects the company's overall approach to executive incentives.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are expected to vest on June 5, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC filing, insider transaction, restricted share units, RSU, director compensation, stock ownership, equity compensation